Elevance Health, Inc. $ELV Position Cut by Gabelli Funds LLC

Gabelli Funds LLC decreased its position in shares of Elevance Health, Inc. (NYSE:ELV) by 65.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,210 shares of the company’s stock after selling 7,990 shares during the quarter. Gabelli Funds LLC’s holdings in Elevance Health were worth $1,232,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Liberty One Investment Management LLC boosted its position in shares of Elevance Health by 1,450.0% during the first quarter. Liberty One Investment Management LLC now owns 930 shares of the company’s stock worth $272,000 after buying an additional 870 shares during the period. Bank of Nova Scotia increased its position in Elevance Health by 77.9% in the 1st quarter. Bank of Nova Scotia now owns 237,998 shares of the company’s stock valued at $69,674,000 after acquiring an additional 104,212 shares during the period. Sei Investments Co. increased its position in Elevance Health by 14.3% in the 1st quarter. Sei Investments Co. now owns 204,457 shares of the company’s stock valued at $59,854,000 after acquiring an additional 25,631 shares during the period. Cetera Investment Advisers raised its stake in Elevance Health by 19.8% during the 1st quarter. Cetera Investment Advisers now owns 97,014 shares of the company’s stock valued at $28,401,000 after acquiring an additional 16,058 shares in the last quarter. Finally, WealthCollab LLC raised its stake in Elevance Health by 42.2% during the 1st quarter. WealthCollab LLC now owns 91 shares of the company’s stock valued at $27,000 after acquiring an additional 27 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ELV shares. Mizuho increased their price target on Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a research note on Monday, June 8th. Wall Street Zen downgraded shares of Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Jefferies Financial Group decreased their target price on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Robert W. Baird boosted their price target on shares of Elevance Health from $331.00 to $393.00 and gave the stock a “neutral” rating in a research report on Thursday, July 16th. Finally, Evercore reaffirmed a “hold” rating on shares of Elevance Health in a research note on Tuesday, May 19th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $440.90.

Insider Buying and Selling at Elevance Health

In other news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the transaction, the director owned 10,734 shares of the company’s stock, valued at $4,312,599.18. The trade was a 1.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.34% of the company’s stock.

Elevance Health Stock Down 0.1%

ELV opened at $375.71 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.52 and a current ratio of 1.52. The company has a market capitalization of $81.48 billion, a PE ratio of 16.70, a P/E/G ratio of 2.16 and a beta of 0.67. The stock’s fifty day moving average is $397.38 and its 200-day moving average is $356.68. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $436.24.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, beating the consensus estimate of $6.21 by $1.24. The business had revenue of $49.83 billion during the quarter, compared to analysts’ expectations of $48.88 billion. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The company’s quarterly revenue was up .8% on a year-over-year basis. During the same quarter last year, the business posted $8.84 earnings per share. On average, equities analysts predict that Elevance Health, Inc. will post 27.04 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Thursday, September 10th will be given a dividend of $1.72 per share. The ex-dividend date is Thursday, September 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. Elevance Health’s dividend payout ratio (DPR) is 30.58%.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Insider buying and investor support are improving sentiment. The company was named a “Pick of the Week” by Smart Insider after its CEO and chairman purchased shares, while a separate analysis said investor favor is strengthening ELV’s rebound. Such purchases can signal management confidence that the stock is undervalued. Elevance Health Pick of the Week at Smart Insider Following CEO, Chairman Share Purchases Investors’ Favour Strengthens Elevance Health’s Rebound
• Positive Sentiment: UnitedHealth Group’s results provide a favorable industry read-through. Improved margins, a lower medical-cost ratio and raised earnings guidance at UnitedHealth suggest that health insurers may be gaining better control over medical costs, potentially supporting expectations for an Elevance turnaround. UnitedHealth Just Gave Wall Street a Clearer Turnaround Signal
• Positive Sentiment: Long-term earnings forecasts were broadly raised. Zacks increased its FY2026 EPS estimate to $27.06, FY2027 to $28.83 and FY2028 to $32.49, above its previous forecasts and roughly consistent with or above the current-year consensus of $27.04.
• Neutral Sentiment: Recent trading has lagged peers. ELV underperformed competitors in the latest reported session, indicating that investors remain selective despite the broader recovery narrative. Elevance Health Inc. stock underperforms Wednesday when compared to competitors
• Negative Sentiment: Near-term earnings expectations were reduced. Zacks cut Q3 2026 EPS to $4.60 from $5.10 and Q4 EPS to $2.43 from $2.95, raising concerns about medical-cost pressure and near-term profitability.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.